Subanesthetic Dose Ketamine Does Not Induce an Affective Switch in Three Independent Samples of Treatment-Resistant Major Depression
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
In the August 15, 2011, issue of Biological Psychiatry, Ricke and colleagues (1) presented a 42-year-old female patient with a history of reflex sympathetic dystrophy, depression, and insomnia admitted for the treatment of intractable pain. Her outpatient medications (duloxetine, mirtazapine, quetiapine, and high-dose opioids) were held at admission, and she received intravenous ketamine (.1–.2 mg/kg for 5 days) for analgesia. During this time, she developed symptoms consistent with mania (euphoric mood, decreased need for sleep, grandiose ideas, and loose associations) that the authors attributed to ketamine. However, there are at least four other diagnostic possibilities that have not been conclusively ruled out. First, the authors stated that the patient “appeared over-sedated and admitted to selfadministering opioids from a supply she kept in her purse, but when asked to, she was reluctant to turn these over to her physicians.” In the context of potential opioid intoxication, delirium must be ruled out (her level of attention and cognition during the hospitalization were not reported). Second, if the patient was self-administering opioids and reluctant to relinquish them to her inpatient providers, she may also have been using other illicit substances with analgesic properties that explain her manic-like syndrome (e.g., cocaine use). Unfortunately, there was no report of urine toxicology. Third, excessive opioid administration can cause a substance-induced mood disorder analogous a to mania in some patients. Finally, Ms. M.’s manic-like presentation occurred in the context of multiple medication adjustments (including increasing duloxetine on Day 8 in the midst of purported mania). Thus, antidepressant-induced mania is another important diagnostic consideration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Self-citationZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 1×
“In our randomized, controlled, crossover studies in major depressive disorder (2) and bipolar depression (4,8), 3 of 44 (7%) subjects who received placebo and 5 of 52 (10%) subjects who received ketamine had maniclike worsening (7).”
BackgroundSelf-citationDiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564 · cited 1×
“In our randomized, controlled, crossover studies in major depressive disorder (2) and bipolar depression (4,8), 3 of 44 (7%) subjects who received placebo and 5 of 52 (10%) subjects who received ketamine had maniclike worsening (7).”
BackgroundSelf-citationIbrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309
Self-citation
Cited by
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
“, dissociative symptoms) in BD patients, the risk of switch from depression to mania remains to be reported.(51,52) However, two case reports showed ketamine-induced switch from depression to mania in treatmentresistant patients.”
BackgroundThe role of ketamine in treatment-resistant depression: A systematic review
Serafini, G., Howland, R., Rovedi, F., Girardi, P., & Amore, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140619204251 · Cited by 234
“[37] evaluated 22 patients with TRD who received placebo or intravenous ketamine (.”
InfluentialIadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315579059 · Cited by 201
Self-citationAn update on ketamine and its two enantiomers as rapid-acting antidepressants
Zhang, K., & Hashimoto, K. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1554434 · Cited by 132
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Lener, M. S., Kadriu, B., & Zarate, C. A. (2017) · Drugs · doi:10.1007/s40265-017-0702-8 · Cited by 131
“In addition, it is important to note that despite the hypothetically increased risk of developing mania or psychosis in response to an NMDA receptor antagonist, the risk of developing mania in response to a single ketamine infusion does not appear to be greater in patients with bipolar depression who are concurrently…”
InfluentialSelf-citation
Metadata
- Authors
- Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Mathews, D. C., Richards, E. M., & Zarate, C. A.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 74
- Issue
- 10
- Pages
- e23-e24
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2043644289
- Cited by
- 39
- References
- 4
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subanesthetic Dose Ketamine Does Not Induce an Affective Switch in Three Independent Samples of Treatment-Resistant Major Depression. https://app.cochat.ai/papers/10.1016/j.biopsych.2013.01.038
- The paper
- Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Mathews, D. C., Richards, E. M., & Zarate, C. A. (2013). Subanesthetic Dose Ketamine Does Not Induce an Affective Switch in Three Independent Samples of Treatment-Resistant Major Depression. Biological Psychiatry. https://doi.org/10.1016/j.biopsych.2013.01.038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.